Advancing a short-course, G6PD test-independent therapy designed to eliminate dormant liver-stage
malaria and prevent relapse

AliquantumRx Inc. today announced positive regulatory feedback from its Type B pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of cethromycin hydrochloride (Cethromycin HCl) for liver-stage malaria.

AliquantumRx Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the

AliquantumRx Inc. announced today the execution of a new collaborative research agreement with The Johns Hopkins

AliquantumRx Inc., a Johns Hopkins FastForward company supported by Maryland Technology Development Corporation (TEDCO) is

AliquantumRx Inc., a Johns Hopkins FastForward company supported by Maryland Technology Development Corporation (TEDCO) is proud to announce the approval of its patent “Salts and Polymorphs of Cethromycin for the Treatment of Bacterial and Protozoan Disease” in People’s Republic of China. The Chinese patent number is patent number CN 115003309 B.

AliquantumRx Inc. signed an MTA with the University of Georgia to study the efficacy of Cethromycin-HCl in vitro against dormant hypnozoites. The work will be performed in the laboratory of Dr. Chester Joyner, Assistant Professor at UGa. Dr. Joyner developed culture system for high-throughput screening to prime and accelerate anti-P. vivax drug discovery efforts.

The United States Army Medical Research Institute of Infectious Diseases evaluated the in vitro antimicrobial activity of cethromycin-HCL against bacterial biothreat pathogens Bacillus anthracis (BA), Francisella tularensis (FT), Yersinia pestis (YP), Burkholderia mallei (BM), and Burkholderia pseudomallei (BP).

AliquantumRx Inc., a Johns Hopkins FastForward company supported by Maryland Technology Development Corporation (TEDCO) is proud to announce the approval of its patent “Salts and Polymorphs of Cethromycin for the Treatment of Bacterial and Protozoan Disease”.

AliquantumRx Inc. signed a Cooperative Research and Development Agreement with The United States Army Medical Research Institute of Infectious Diseases to evaluate the in vitro antimicrobial activity of cethromycin-HCL against bacterial biothreat pathogens Bacillus anthracis (BA), Francisella tularensis (FT), Yersinia pestis (YP), Burkholderia mallei (BM), and Burkholderia pseudomallei (BP).

David Sullivan, MD, Johns Hopkins University receives a 3 year CDMRP grant entitled “A Pharmacokinetic

Patent Cooperation Treaty Application Salts and Polymorphs of Cethromycin for the Treatment of Disease PCT/US2020/062882

Clinical Trial Success Story: David Sullivan, MD, JHU-led Team Study Finds Convalescent Plasma Can Be

Patent Cooperation Treaty Application Salts and Polymorphs of Cethromycin for the Treatment of Disease is

Global Patent Group, LLC files a Patent cooperation treaty (PCT) application PCT/US20/62882 on December 2,

 AliquantumRx Inc. announces a phase III MII funding for a project entitled “Development of Cethromycin

AliquantumRx Inc. announces the filing of a provisional patent application No. 62/942,508 entitled “Salts and

AliquantumRx Inc. announces that it has attracted an initial capital investment of up to $500,000

AliquantumRx Inc. has entered into a licensing agreement with JHTV for all of their IP

Johns Hopkins Technology Ventures files for nationalization of PCT/US15/46665.